OctreoPharm Sciences announced that the FDA has granted Orphan Drug designation to OPS202, an investigational radiotracer, based on a next generation antagonistic somatostatin analog for the management of neuroendocrine tumors.
RELATED: Oncology Resource Center
OPS202 is currently being studied in Phase 1/2 clinical trials. It has the potential to improve imaging of neuroendocrine tumor patients, which may lead to a change in disease management of those patients. Since the peptide can deliver up to 5 times more dose to the tumor compared to currently used second-generation agonists like DOTA-TATE, DOTA-TOC or DOTA-NOC, OctreoPharm Sciences is developing the same peptide as an therapeutic drug (OPS201) following a Theranostic approach.
For more information visit OctreoPharm.com.